Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market was valued at USD 1.2 Billion in 2022 and is projected to reach USD 3.8 Billion by 2030, growing at a CAGR of 16.3% from 2024 to 2030.
The Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market is witnessing significant growth, driven by increasing healthcare needs and advancements in diabetes management. GLP-1-based therapies are increasingly being recognized as essential treatment options for managing type 2 diabetes, particularly in Japan, where the aging population and high prevalence of diabetes have led to a surge in demand for effective therapies. These therapies include GLP-1 receptor agonists, which play a crucial role in regulating blood sugar levels, enhancing insulin secretion, and reducing glucagon production.
In Japan, GLP-1-based therapies are quickly becoming a preferred treatment due to their dual benefit of controlling blood glucose levels and promoting weight loss. The therapy works by mimicking the natural hormone GLP-1, which is typically secreted after eating. This process helps to regulate blood sugar levels by stimulating insulin release and suppressing glucagon production, ultimately leading to lower blood sugar and better glycemic control.
The demand for these therapies is fueled by the country's increasing number of type 2 diabetes patients and the rise in obesity rates, making GLP-1 a crucial treatment option. Japan’s medical landscape is evolving, with healthcare providers increasingly relying on these therapies for long-term diabetes management. The requirement for these therapies spans various industries, particularly in pharmaceutical companies, healthcare providers, and diabetes care centers, which are keen on offering advanced, effective, and innovative solutions to patients. Pharmaceutical manufacturers are continuously researching and developing new GLP-1-based products to cater to this growing demand, ensuring that these therapies are available in both injectable and oral forms to offer better convenience to patients.
As Japan's healthcare system adapts to the changing demographic and medical needs of its population, the GLP-1-based therapies market is expected to continue its expansion. In addition to diabetes, the therapies are also being explored for their potential benefits in managing obesity, cardiovascular diseases, and other metabolic conditions. The increased focus on patient-centric healthcare solutions and the push for personalized medicine are expected to fuel further advancements in this sector, making GLP-1-based therapies a staple in the Japanese healthcare market.
Get an In-Depth Research Analysis of the Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size And Forecast [2025-2032]
Â
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market
Short-acting GLP-1 Agonists
Long-acting GLP-1 Agonists
Combination Therapy with Insulin
Oral GLP-1 Agonists
Generic GLP-1 Drugs
Type 2 Diabetes Mellitus
Obesity Management
Cardiovascular Disease Prevention
Non-Alcoholic Fatty Liver Disease (NAFLD)
Weight Loss in Diabetic Patients
Subcutaneous Injection
Intravenous Administration
Oral Route
Inhalation
Transdermal Delivery Systems
Adults
Pediatric Patients
Geriatric Patients
Pregnant Women
Patients with Comorbid Conditions
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
Healthcare Institutions
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Analysis
1. Introduction of the Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market, By Type
6. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market, By Application
7. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/